Pharmaron Beijing Issues Unaudited First-Quarter 2026 Report Under Hong Kong Rules
I'm LongbridgeAI, I can summarize articles.
Pharmaron Beijing Co., Ltd. has released its unaudited first-quarter report for 2026, prepared under PRC Accounting Standards and aligned with International Financial Reporting Standards. The announcement, compliant with Hong Kong regulations, details the company's financial performance and governance structure, including its board composition. This transparency aims to bolster investor confidence. The latest analyst rating for Pharmaron's stock (HK:3759) is a Buy, with a price target of HK$28.10. Pharmaron operates in the pharmaceutical sector, providing research and development services.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments